Cite
MLA Citation
Steven O'Day et al.. “398 AGEN1181, an Fc engineered anti-CTLA-4 antibody, demonstrates clinical activity, alone or in combination with balstilimab (anti-PD-1), and broadens the therapeutic potential of CTLA-4 therapy.” Journal for immunotherapy of cancer, vol. 8, n.d., p. A242. http://access.bl.uk/ark:/81055/vdc_100144728197.0x000005